Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

Neuropharmacology

Volumn 43, Issue 7, 2002, Pages 1110-1118

  Finberg, John P M ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Dopamine; Monoamine oxidase A and B inhibitors; Noradrenaline; Parkinson's disease; Rasagiline; Selegiline; Serotonin; Tyramine

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BRAIN MONOAMINE; DOPAMINE; FLUOXETINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; RASAGILINE; RESERPINE; SELEGILINE; SEROTONIN; TRANYLCYPROMINE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; HYPERACTIVITY; MALE; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PTOSIS; RAT; SEROTONINERGIC SYSTEM;

EID: 0036914093     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00216-2     Document Type: Article

References (43)

1. Ashkenazi R., Finberg J.P.M., Youdim M.B.H. Behavioural response to combined treatment with inhibitors of MAO and the selective inhibitor of 5-HT uptake, LM 5008. British Journal of Pharmacology. 79:1983;765-770.
2. Birkmayer W., Riederer P., Youdim M.B.H., Linauer W. The potentiation of anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. Journal of Neural Transmission. 36:1975;303-326.
3. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B.H. Implications of combined treatment with Madopar and l-deprenyl in Parkinson's disease. Lancet. 2:1977;439-443.
4. Campbell I.C., Robinson D.S., Lovenberg W., Murphy D.L. The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in rat brain. Journal of Neurochemistry. 32:1979;49-55.
5. Churchyard A., Matthias C.J., Boonkongchuen P., Lees A.J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 63:1997;228-234.
6. Eisler T., Teravainen H., Nelson R., Krebs H., Weise V., Lake C.R., Ebert M.H., Whetzel N., Murphy D.L., Kopin I.J., Calne D.B. Deprenyl in Parkinson's disease. Neurology. 31:1981;19-23.
7. Finberg J.P.M., Sabbagh A., Youdim M.B.H. Pharmacology of selective propargyl suicide inhibitors of monoamine oxidase. Usdin E., Sourkes T.L., Youdim M.B.H. Enzymes and Neurotransmitters in Mental Disease. 1980;207-219 Wiley, Chichester.
8. Finberg J.P.M., Wang J., Goldstein D.S., Kopin I.J., Bankiewicz K.S. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. Journal of Neurochemistry. 65:1995;1213-1220.
9. Finberg J.P.M., Lamensdorf I., Commissiong J.W., Youdim M.B.H. Pharmacology and neuroprotective properties of rasagiline. Journal of Neural Transmission. 48:1996;95-103.
10. Finberg J.P.M., Takeshima T., Johnston J.M., Commissiong J.W. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 9:1998;703-707.
11. Finberg J.P.M., Lamensdorf I., Weinstock M., Schwartz M., Youdim M.B.H. Pharmacology of rasagiline (N-propargyl-IR-aminoindan). Advances in Neurology. 80:1999;495-501.
12. 3H]dopa in various regions of the brain. Journal of Neurochemistry. 13:1966;655-659.
13. Glowinski J., Hamon M., Javoy F., Morot-Gaudry Y. Rapid effects of monoamine oxidase inhibitors on synthesis and release of central monoamines. Costa E., Sandler M. Monoamine Oxidases - New Vistas. 1972;423-439 Raven Press, New York.
14. Green A.R., Youdim M.B.H. Effects of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. British Journal of Pharmacology. 55:1975;415-422.
15. Green A.R., Grahame-Smith D.G. Effects of drugs on the processes regulating the functional activity of 5-hydroxytryptamine. Nature. 260:1976;487-491.
16. Green A.R., Tordoff A., Mitchel B., Youdim M.B.H. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for degree of inhibition of enzyme necessary for increased function and activity of dopamine and 5-hydroxytryptamine. British Journal of Pharmacology. 60:1977;343-349.
17. Hida T., Hasegawa Y., Arai R. Histochemical study of dopamine-degrading monoamine oxidase activity in dopaminergic neurons of rat brain. Brain Research. 842:1999;491-495.
18. Huang W., Chen Y., Shohami E., Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase B inhibitor, against head injury in the mouse. European Journal of Pharmacology. 366:1999;127-135.
19. Juorio A.V., Li X.-M., Paterson A., Boulton A.A. Effects of monoamine oxidase B inhibitors on dopaminergic function: role of 2-phenylethylamine and aromatic L-amino acid decarboxylase. Lieberman A., Olanow C.W., Youdim M.B.H., Tipton K. Monoamine Oxidase Inhibitors in Neurological Diseases. 1994;181-200 Dekker, New York.
20. Koller W.C. Neuroprotection for Parkinson's disease. Annals of Neurology. 44:(1):1998;S155-S159.
21. Kuhn D.M., Wolf W.A., Youdim M.B. 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the-5HT behavioural syndrome in reserpinized rats. British Journal of Pharmacology. 84:1985;121-129.
22. Lamensdorf I., Youdim M.B.H., Finberg J.P.M. The effect of long term treatment with monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Journal of Neurochemistry. 67:1996;1532-1539.
23. Lamensdorf I., Finberg J.P.M. Reduced striatal tyrosine hydroxylase activity is not accompanied by change in responsiveness of dopaminergic receptors following chronic treatment with deprenyl. Neuropharmacology. 36:1997;1455-1461.
24. Maitre, L., Delini-Stula, A., Waldmeier, P.C., 1976. Relation between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors. Ciba Foundation Symposium No. 39, Elsevier: Amsterdam, pp. 247-267.
25. Maruyama W., Yamamoto T., Kitani K., Carrillo M.C., Youdim M., Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mechanisms of Ageing and Development. 116:2000;181-191.
26. Neff N.H., Fuentes J.A. The use of selective monoamine oxidase inhibitor drugs for evaluating pharmacological and physiological mechanisms. Wolstenholme G.E.W., Knight J. Monoamine Oxidase and its Inhibition. 1976;163-173 Excerpta Medica, Amsterdam.
27. O'Carroll A.M., Fowler C.J., Phillip J.P., Tobia I., Tipton K.F. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two forms in seven brain regions. Naunyn Schmiedeberg's Archives of Pharmacology. 322:1983;198-207.
28. Parkinson Study Group (2000). A controlled study with rasagiline in early Parkinson's disease. Proc. Am. Neurol. Assoc., Boston, MA, p. 178.
29. Rabey J.M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., Inzelberg R., Djaldetti R., Klein C., Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clinical Neuropharmacology. 23:2000;324-330.
30. Richards J.G., Saura J., Luque J.M., Cesura A.M., Gottowik J., Malherbe P., Borroni E., Gray J. Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology. Journal of Neural Transmission. 53:1998;173-187.
31. Riederer P., Youdim M.B.H. Monoamine oxidase activity and monoamine metabolism in brains of Parkinson patients treated with l-deprenyl. Journal of Neurochemistry. 46:1986;1359-1365.
32. Simpson L.L. Evidence that deprenyl, a type B monoamine oxidase inhibitor is an indirectly acting sympathomimetic amine. Biochemical Pharmacology. 27:1978;1591-1595.
33. Sterling J., Veinberg A., Lerner D., Goldenberg W., Levy R., Youdim M.B.H., Finberg J.P.M. (R)(+)-N-Propargyl-l-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. Journal of Neural Transmission. 52:1998;301-305.
34. Tatton W.G., Chalmers-Redman R.M.E. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 47:(3):1996;S171-S183.
35. Twist E.C., Mitchell S.N., Corn T.H., Campbell I.C. Effects of chronic ritanserin or clorgyline on amine and metabolite levels in rat frontal cortex. European Journal of Pharmacology. 196:1991;157-160.
36. Vrana S.L., Azzaro A.J., Vrana K.E. Chronic selegiline admnistration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Molecular Pharmacology. 41:1992;839-844.
37. Waldmeier P.C., Felner A.E., Maitre L. Long-term effects of selective MAO inhibitors on MAO activity and amine metabolism. Youdim M.B.H., Paykel E.S. Monoamine Oxidase Inhibitors, the State of the Art. 1981;87-102 Wiley, New York.
38. Wan F.J., Lin H.C., Huang K.L., Tseng C.J., Wong C.S. Systemic administration of d-amphetamine induces long-lasting oxidative stress in the rat striatum. Life Sciences. 66:2000;PL205-212.
39. Weiner N. Regulation of norepinephrine biosynthesis. Annual Reviews in Pharmacology. 10:1970;273-290.
40. Willoughby J., Glover V., Sandler M. Histochemical localization of monoamine oxidase A and B in rat brain. Journal of Neural Transmission. 74:1988;29-42.
41. Yang H.Y.T., Neff N.H. The monoamine oxidase of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. Journal of Pharmacology and experimental Therapy. 189:1974;733-740.
42. Yasar S., Goldberg J.P., Goldberg S.R. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. Journal of Neural Transmission. 48:(Suppl):1996;61-73.
43. Youdim M.B.H., Gross A., Finberg J.P.M. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British Journal of Pharmacology. 132:2001;500-506.